Roche Holding AG (SWX: RO)
Switzerland
· Delayed Price · Currency is CHF 261.20
+0.20 (0.08%)
Dec 20, 2024, 5:30 PM CET
Roche Holding AG Revenue
Roche Holding AG had revenue of 30.76B CHF in the half year ending June 30, 2024, a decrease of -9.27%. This brings the company's revenue in the last twelve months to 60.58B, down -3.12% year-over-year. In the year 2023, Roche Holding AG had annual revenue of 60.44B, down -8.16%.
Revenue (ttm)
60.58B
Revenue Growth
-3.12%
P/S Ratio
n/a
Revenue / Employee
584.73K
Employees
103,605
Market Cap
198.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | 63.75B | 4.25B | 7.15% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 60.58B |
| Novartis AG | 42.18B |
| Lonza Group AG | 6.70B |
| Galderma Group AG | 3.88B |
| Straumann Holding AG | 2.54B |
| Sonova Holding AG | 3.71B |
| Ypsomed Holding AG | 617.07M |
| Galenica AG | 3.80B |
Roche Holding AG News
- 2 days ago - Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits - Benzinga
- 2 days ago - Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study - The Wall Street Journal
- 2 days ago - Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study - WSJ
- 2 days ago - Roche, Prothena miss main goal in mid-stage trial for Parkinson’s drug - Seeking Alpha
- 2 days ago - Roche Halts Development of SPK-8011 Amid Strategic Gene Therapy Focus - GuruFocus
- 2 days ago - Roche's Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson's disease - GlobeNewsWire
- 2 days ago - Genentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's Disease - Business Wire
- 3 days ago - Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche - Investor's Business Daily